KR20120049900A - 항원성 타우 펩타이드 및 이의 용도 - Google Patents

항원성 타우 펩타이드 및 이의 용도 Download PDF

Info

Publication number
KR20120049900A
KR20120049900A KR1020127005415A KR20127005415A KR20120049900A KR 20120049900 A KR20120049900 A KR 20120049900A KR 1020127005415 A KR1020127005415 A KR 1020127005415A KR 20127005415 A KR20127005415 A KR 20127005415A KR 20120049900 A KR20120049900 A KR 20120049900A
Authority
KR
South Korea
Prior art keywords
peptide
tau
antigenic
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020127005415A
Other languages
English (en)
Korean (ko)
Inventor
3세 조지 조셉 스미스
켄네스 넬슨 윌스
제프 시안카오 주
Original Assignee
화이자 백신스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 백신스 엘엘씨 filed Critical 화이자 백신스 엘엘씨
Publication of KR20120049900A publication Critical patent/KR20120049900A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020127005415A 2009-07-30 2010-07-20 항원성 타우 펩타이드 및 이의 용도 Abandoned KR20120049900A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22986009P 2009-07-30 2009-07-30
US61/229,860 2009-07-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137028550A Division KR20130127547A (ko) 2009-07-30 2010-07-20 항원성 타우 펩타이드 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20120049900A true KR20120049900A (ko) 2012-05-17

Family

ID=42941871

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127005415A Abandoned KR20120049900A (ko) 2009-07-30 2010-07-20 항원성 타우 펩타이드 및 이의 용도
KR1020137028550A Ceased KR20130127547A (ko) 2009-07-30 2010-07-20 항원성 타우 펩타이드 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137028550A Ceased KR20130127547A (ko) 2009-07-30 2010-07-20 항원성 타우 펩타이드 및 이의 용도

Country Status (17)

Country Link
US (1) US20110177109A1 (enExample)
EP (1) EP2459214A1 (enExample)
JP (1) JP2013500326A (enExample)
KR (2) KR20120049900A (enExample)
CN (1) CN102596236B (enExample)
AR (1) AR078085A1 (enExample)
AU (1) AU2010277254B2 (enExample)
CA (1) CA2768346A1 (enExample)
CO (1) CO6612199A2 (enExample)
IN (1) IN2012DN00446A (enExample)
MX (1) MX2012001194A (enExample)
NZ (2) NZ618391A (enExample)
PE (1) PE20120817A1 (enExample)
RU (2) RU2518291C2 (enExample)
SG (1) SG177637A1 (enExample)
TW (2) TW201436804A (enExample)
WO (1) WO2011013034A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101329374B1 (ko) 2008-12-09 2013-11-14 콜레이 파마시티컬 그룹, 인코포레이티드 면역자극성 올리고뉴클레오타이드
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
EP4218794A3 (en) * 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
WO2012045882A2 (en) * 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
US9239332B2 (en) 2011-07-11 2016-01-19 Indi Molecular, Inc. Akt-specific capture agents, compositions, and methods of using and making
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
JP6358953B2 (ja) 2011-10-07 2018-07-18 エーシー イミューン エス．エー． タウを認識するホスホ特異的抗体
CA2869438C (en) 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
EP2870176A4 (en) * 2012-07-03 2016-09-28 Univ Washington ANTIBODIES DIRECTED AGAINST TAU
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
MX374811B (es) 2013-03-15 2025-03-06 Ac Immune Sa Anticuerpos anti-tau y métodos de uso.
EP3027205A4 (en) * 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
EP3166688B1 (en) 2014-07-08 2024-08-21 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
WO2016154522A1 (en) * 2015-03-25 2016-09-29 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
CA2991264C (en) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
IL256833B2 (en) 2015-07-15 2025-07-01 California Inst Of Techn IL-17F-specific binding agents, compositions and methods of use and preparation
US10988528B2 (en) 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
WO2017176769A1 (en) 2016-04-04 2017-10-12 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
EP3519425B1 (en) 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
EP3638687A1 (en) 2017-06-15 2020-04-22 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
JP2021508673A (ja) 2017-10-27 2021-03-11 ユナイテッド ニューロサイエンスＵｎｉｔｅｄ Ｎｅｕｒｏｓｃｉｅｎｃｅ タウペプチド免疫原構築物
CN109870581B (zh) * 2017-12-04 2021-05-04 厦门万泰凯瑞生物技术有限公司 一种定量检测HBsAg的试剂盒及方法
CN108314737B (zh) * 2018-01-25 2021-03-16 中国科学院过程工程研究所 一种重组蛋白及其制备方法和应用
CN110548135B (zh) 2018-05-31 2023-06-06 长春百克生物科技股份公司 磷酸化多肽抗原疫苗及其制备方法和应用
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
JP7719713B2 (ja) 2018-10-07 2025-08-06 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア α－シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
SG11202106717PA (en) * 2019-02-08 2021-07-29 Prothena Biosciences Ltd Antibodies recognizing tau
US20200291391A1 (en) * 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
CN113874078B (zh) 2019-04-05 2025-05-06 Tauc3生物制品有限公司 抗tauc3抗体及其应用
MX2021012994A (es) 2019-04-24 2022-03-04 Janssen Pharmaceuticals Inc Administracion heterologa de vacunas tau.
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
EP3976793A4 (en) * 2019-05-27 2023-06-21 The University of British Columbia CONFORMATION-SPECIFIC EPITOPES IN TAU, ANTIBODIES AGAINST IT AND METHODS RELATED THERETO
GB2585252A (en) * 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
IL300346A (en) * 2020-08-07 2023-04-01 Prothena Biosciences Ltd TAU vaccine for the treatment of Alzheimer's disease
CN116472055A (zh) 2020-08-07 2023-07-21 欧萨尔普罗席纳有限公司 治疗阿尔兹海默氏病的多表位疫苗
WO2022054795A1 (ja) * 2020-09-08 2022-03-17 国立大学法人大阪大学 リン酸化タウタンパク質を標的とする免疫原性組成物
TW202321312A (zh) * 2021-09-08 2023-06-01 俄羅斯聯邦商拜奧卡德聯合股份公司 包含基於ｍｈｃ或ｍｈｃ樣蛋白的異源二聚體的二價雙特異性嵌合抗體
EP4408864A4 (en) * 2021-09-29 2025-09-03 Janssen Pharmaceuticals Inc METHOD FOR SAFE ADMINISTRATION OF A TAU PHOSPHOPEPTIDE CONJUGATE
CN115894659B (zh) * 2022-10-19 2023-11-10 上海优宁维生物科技股份有限公司 微管相关蛋白Tau抗原及其制备方法和应用
WO2025227011A1 (en) * 2024-04-26 2025-10-30 Unm Rainforest Innovations Immunotherapy compositions and methods for treatment of tauopathy, neuroinflammation, and synaptic loss
CN121513188B (zh) * 2025-12-30 2026-07-28 长沙诺盟生物医药有限公司 一种复合疫苗佐剂及其制备方法和应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
EP0092574B1 (en) 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
DE3525624A1 (de) 1985-07-18 1987-01-22 Celamerck Gmbh & Co Kg Insektizid wirksames mittel zur bekaempfung von textilschaedlingen
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
WO1993011231A1 (en) * 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
WO1998055609A1 (en) 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
JP4480268B2 (ja) 1998-02-12 2010-06-16 イミューン コンプレックス コーポレイション 戦略的修飾されたｂ型肝炎コアタンパク質及びそれらの誘導体
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
WO2000023955A1 (en) 1998-10-21 2000-04-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Virus-like particles for the induction of autoantibodies
DK1119630T3 (da) 1998-11-05 2006-05-15 Powderject Vaccines Inc Nukleinsyrekonstruktioner til genetisk immunisering
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
IL148671A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
HK1049106A1 (zh) 1999-09-24 2003-05-02 Smithkline Beecham Biologicals S.A. 聚氧化乙烯山梨糖酯和octooxynol的聯用做為佐劑和其在疫苗中的用途
JP4713809B2 (ja) 2000-04-07 2011-06-29 ユニバーシティ オブ リードズ イノベイションズ リミテッド Ｂ型肝炎コア抗原融合タンパク質
EP1278542A2 (en) 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
ATE320493T1 (de) 2000-06-22 2006-04-15 Ucb Pharma Ltd Modifizierung des hepatitis b kernantigens
AU2001269272A1 (en) 2000-07-15 2002-01-30 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
WO2003102165A2 (en) 2002-02-21 2003-12-11 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US20040176283A1 (en) 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
AU2003246690B2 (en) 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
BR0312792A (pt) * 2002-07-19 2005-05-03 Cytos Biotechnology Ag Composições de vacinas contendo séries antigênicas de amilóide beta1-6
CA2509484C (en) 2002-12-10 2012-03-20 Lorantis Ltd. Stabilized immunogenic hbc chimer particles
SG149013A1 (en) * 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
ES2348312T3 (es) * 2006-04-13 2010-12-02 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vacuna her-2/neu a base de múltiples péptidos.
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
EP4218794A3 (en) * 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
FR3058624B1 (fr) 2016-11-15 2018-12-07 L'oreal Brosse pour l'application d'un produit sur les cils et/ou les sourcils

Also Published As

Publication number Publication date
US20110177109A1 (en) 2011-07-21
AU2010277254A1 (en) 2012-02-09
EP2459214A1 (en) 2012-06-06
MX2012001194A (es) 2012-03-07
KR20130127547A (ko) 2013-11-22
AR078085A1 (es) 2011-10-12
JP2013500326A (ja) 2013-01-07
SG177637A1 (en) 2012-03-29
CA2768346A1 (en) 2011-02-03
CN102596236A (zh) 2012-07-18
PE20120817A1 (es) 2012-07-07
RU2014112002A (ru) 2015-10-10
TWI461209B (zh) 2014-11-21
TW201106968A (en) 2011-03-01
RU2518291C2 (ru) 2014-06-10
RU2012102701A (ru) 2013-09-10
CN102596236B (zh) 2015-06-24
WO2011013034A1 (en) 2011-02-03
IN2012DN00446A (enExample) 2015-05-15
AU2010277254B2 (en) 2015-05-07
CO6612199A2 (es) 2013-02-01
TW201436804A (zh) 2014-10-01
NZ598356A (en) 2014-06-27
NZ618391A (en) 2015-07-31
WO2011013034A4 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
AU2010277254B2 (en) Antigenic tau peptides and uses thereof
JP5964280B2 (ja) ＩｇＥＣＨ３ペプチドワクチン
AU2013204233B2 (en) IgE CH3 peptide vaccine
HK1173376A (en) Antigenic tau peptides and uses thereof
HK1163511B (zh) Ige ch3肽疫苗

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20120229

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120229

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130829

Patent event code: PE09021S01D

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20131029

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140328

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20141030

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140328

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20130829

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20141030

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20140528

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20131029

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20150226

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150130

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20141030

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140528

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20140328

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20131029

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20130829

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20150330

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20150226

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20141030

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20161129

Appeal identifier: 2015101001742

Request date: 20150330

J301 Trial decision

Free format text: TRIAL NUMBER: 2015101001742; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20150330

Effective date: 20161129

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20161129

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20150330

Decision date: 20161129

Appeal identifier: 2015101001742

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20161214

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20161208

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee